MLTX MoonLake Corp: Price-to-Projected Revenue Ratio

MoonLake Immunotherapeutics - graphic logo of issuer MLTX

MoonLake Immunotherapeutics develops liver therapies in the US and Switzerland. The projected P/S value confirms the market valuation, where the metric determines this level. An agile staff of scientists motivated by stock options is driving the company's development. However, success depends on the clinical trial results for sonelokimab and the ability to withstand the expansion of pharmaceutical behemoths.

MoonLake - MLTX Market Cap to Expected Sales Ratio (period 07/04/2022 - 11/16/2026)

Summary analytical data breakdowns for moonlaketx.com (MLTX)

- market price and analyst price targets:
- company stock capitalization data:
Analysis of all company metrics:MLTX (moonlaketx.com)
Original product of MoonLake Immunotherapeutics

MoonLake Immunotherapeutics (MLTX) seeks to mitigate the risks of single-product dependence on sonelokimab by scaling the drug's application across rheumatology and dermatology. The forward P/S ratio compares current market capitalization with projected revenues, allowing this chart's price action to assess whether the market valuation is fair relative to expected revenue and to avoid overpaying for speculative investor optimism.

Competitor analysis

Price-to-Projected Revenue Ratio ascendispharma.com ASND|Madrigal Corp (MDGL) - Market Cap to Future Revenue Ratio|CORT - Price-to-Projected Revenue Ratio|RYTM: Price-to-Projected Revenue Ratio|AKRO: Forward P/S Multiple|MTSR - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Crinetics Corp|NewAmsterdam Pharma Corp (NAMS) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio soleno.life (SLNO)|Forward Price-to-Revenue Multiple Amicus Therapeutics FOLD|Forward Price to Sales 89bio Inc|Forward P/S Multiple Agios Pharmaceuticals, Inc. AGIO|GPCR: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio MiMedx Corp MDXG|RZLT (Rezolute Corp) - Forward Price-to-Revenue Multiple|Market Cap to Projected Revenue LXRX|MBX (MBX Biosciences) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Altimmune Inc (ALT)|Forward Price-to-Revenue Multiple AARD (Aardvark Therapeutics Corp)|Forward Price-to-Revenue Multiple Sagimet SGMT|Forward P/S Multiple BIOA (BioAge Labs)|Forward P/S Multiple Biomea Fusion BMEA|QNCX: Forward Price-to-Revenue Multiple|GUTS: Price-to-Projected Revenue Ratio|vTv Therapeutics Inc (VTVT) - Price-to-Projected Revenue Ratio|ATPC: Price to Expected Revenue Ratio|PLUR (pluri-biotech.com) - Forward P/S Multiple|SYBX: Forward Price to Sales|Forward P/S Multiple LPCN|Market Cap to Expected Sales Ratio Matinas BioPharma Holdings, Inc.|Price-to-Projected Revenue Ratio Spruce Biosciences Inc. SPRB|GLTO - Forward Price-to-Revenue Multiple|CTCX - Price-to-Projected Revenue Ratio|LUMO - Forward P/S Multiple|ONVO: Forward P/S Multiple|RDUS (Radius Recycling) - Price-to-Projected Revenue Ratio